Healthcare & Life Sciences IPO Advisory in India

A healthcare IPO advisor helps companies prepare for listing by assessing readiness, shaping the equity story, coordinating DRHP drafting, supporting SEBI-facing workstreams, building valuation frameworks, and mapping investor demand. For healthcare issuers, this also means translating sector metrics like occupancy, ARPOB, sample volumes, regulatory approvals, and manufacturing compliance into disclosures investors can evaluate clearly.

These services are relevant for Indian hospital chains, diagnostics networks, pharmaceutical manufacturers, biotech firms, medical device companies, CDMOs, CROs, wellness businesses, healthtech platforms, and health-insurance-adjacent companies. The right route depends on scale, profitability, governance maturity, disclosure readiness, and whether the company is better suited for a Main Board or SME listing pathway.

Most growth-stage companies should begin 12 to 18 months before filing, especially if they need governance upgrades, Ind-AS restatement, cap table cleanup, or stronger internal controls. Starting early is particularly useful in healthcare, where accreditation status, payer mix disclosures, regulatory documentation, and specialist concentration risks often need careful preparation before formal diligence begins.

Yes. S45 supports both Main Board listings on NSE and BSE and SME listings on NSE Emerge and BSE SME. The work includes route selection, readiness assessment, drafting support, pricing and distribution planning, and post-listing liquidity strategy. For SME issuers, this can also include market maker coordination, lot size modelling, and migration planning toward the Main Board later.

Valuation is built using sector comparables, business quality, growth visibility, profitability, and investor appetite. For hospitals, investors may focus on occupancy, ARPOB, expansion efficiency, and payer mix. For diagnostics, sample growth and yield matter. For pharma and biotech, regulatory status, pipeline quality, and manufacturing credibility are central. Pricing is then refined through investor soundings and bookbuilding.

Key disclosures vary by sub-sector. Hospitals often need clear reporting on occupancy, ARPOB, specialties, doctor retention, and insurance or government-scheme exposure. Diagnostics companies need sample volumes, network mix, and yield trends. Pharma, biotech, and devices businesses typically require detailed disclosure on regulatory approvals, manufacturing standards, pipeline stages, quality systems, and product concentration risks.

Timelines depend on readiness, route, and regulatory progress. S45 notes that a signed mandate can happen in 7 days and a company may become DRHP-ready in 30 days from a clean data room, but full IPO execution usually takes longer. Main Board processes often run 6 to 12 months, while SME listings may move faster if documentation and governance are already in place.

Post-listing support typically includes investor relations planning, earnings materials, institutional targeting, liquidity monitoring, and preparation for future capital raises. This matters because newly listed healthcare companies need consistent communication around operating metrics, regulatory developments, expansion plans, and quarterly performance. Strong after-market discipline can support trading stability and build credibility with long-term institutional investors.